$OGEN
ORAGENICS INC Stock $ogen

$ogen Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011979 Filed on March 29, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue		$0.00	$37.65K
YoY Change			-71.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.797M	$1.754M	$5.452M
YoY Change	43.82%	98.55%	21.85%
% of Gross Profit
Research & Development	$663.4K	$11.04M	$15.49M
YoY Change	-60.34%	682.05%	53.79%
% of Gross Profit
Depreciation & Amortization	$0.00	-$2.610K	$27.39K
YoY Change	-100.0%	-119.95%	-38.68%
% of Gross Profit
Operating Expenses	$2.460M	$12.80M	$20.94M
YoY Change	-15.8%	457.45%	43.96%
Operating Profit	-$2.460M		-$20.90M
YoY Change	-15.31%		45.02%
Interest Expense	$7.085K	$26.40K	$179.8K
YoY Change	111.68%	-56.85%	1090.49%
% of Operating Profit
Other Income/Expense, Net	$9.270K	$22.50K	$69.36K
YoY Change	-84.54%	-757.89%	-45.49%
Pretax Income	-$2.451M	-$12.75M	-$20.66M
YoY Change	-13.85%	469.66%	44.56%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.451M	-$12.75M	-$20.66M
YoY Change	-13.85%	469.66%	44.56%
Net Earnings / Revenue			-54862.52%
Basic Earnings Per Share	-$0.70		-$9.18
Diluted Earnings Per Share	-$0.70	-$4.92	-$9.18
COMMON SHARES
Basic Shares Outstanding	4.481M shares	2.569M shares	2.250M shares
Diluted Shares Outstanding	3.496M shares		2.250M shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.072M	$3.484M	$3.484M
YoY Change	-77.38%	-69.51%	-69.51%
Cash & Equivalents	$2.072M	$3.484M	$3.484M
Short-Term Investments
Other Short-Term Assets	$371.2K	$382.3K	$382.3K
YoY Change	-85.41%	-86.65%	-86.65%
Inventory
Prepaid Expenses	$237.2K
Receivables
Other Receivables
Total Short-Term Assets	$2.443M	$3.866M	$3.866M
YoY Change	-79.12%	-72.95%	-72.95%
LONG-TERM ASSETS
Property, Plant & Equipment	$0.00	$9.810K	$9.810K
YoY Change	-100.0%	-91.9%	-97.91%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.091M	$1.091M	$1.091M
YoY Change	5979.99%
Total Long-Term Assets	$1.091M	$1.101M	$1.101M
YoY Change	155.79%	134.91%	134.91%
TOTAL ASSETS
Total Short-Term Assets	$2.443M	$3.866M	$3.866M
Total Long-Term Assets	$1.091M	$1.101M	$1.101M
Total Assets	$3.534M	$4.966M	$4.966M
YoY Change	-70.86%	-66.35%	-66.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$695.8K	$1.245M	$1.245M
YoY Change	-25.9%	10.74%	404.66%
Accrued Expenses	$68.77K	$240.5K	$240.5K
YoY Change	-85.92%	-70.41%	-77.77%
Deferred Revenue
YoY Change
Short-Term Debt	$126.8K	$312.7K	$312.7K
YoY Change	17.56%	16.84%	16.84%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$908.7K	$1.798M	$1.798M
YoY Change	-48.97%	12.65%	12.65%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change		-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$908.7K	$1.798M	$1.798M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$908.7K	$1.798M	$1.798M
YoY Change	-51.79%	2.83%	2.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$208.7M	-$206.2M
YoY Change	10.75%	11.13%
Common Stock	$4.480K	$3.081K
YoY Change	121.23%	52.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.625M	$3.168M	$3.168M
YoY Change
Total Liabilities & Shareholders Equity	$3.534M	$4.966M	$4.966M
YoY Change	-70.86%	-66.35%	-66.35%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.451M	-$12.75M	-$20.66M
YoY Change	-13.85%	469.66%	44.56%
Depreciation, Depletion And Amortization	$0.00	-$2.610K	$27.39K
YoY Change	-100.0%	-119.95%	-38.68%
Cash From Operating Activities	-$3.064M	-$1.101M	-$7.291M
YoY Change	45.31%	-54.75%	-52.12%
INVESTING ACTIVITIES
Capital Expenditures		$1.000M	$1.000M
YoY Change		28969.77%	684.2%
Acquisitions
YoY Change
Other Investing Activities		$3.720K	$63.72K
YoY Change			431.0%
Cash From Investing Activities		-$996.3K	-$936.3K
YoY Change		28861.63%	710.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$849.9K
YoY Change			1126.64%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.653M	-176.1K	283.9K
YoY Change	-1134.58%	100.14%	-157.36%
NET CHANGE
Cash From Operating Activities	-$3.064M	-1.101M	-7.291M
Cash From Investing Activities		-996.3K	-936.3K
Cash From Financing Activities	$1.653M	-176.1K	283.9K
Net Change In Cash	-$1.412M	-2.273M	-7.943M
YoY Change	-37.78%	-9.94%	-49.85%
FREE CASH FLOW
Cash From Operating Activities	-$3.064M	-$1.101M	-$7.291M
Capital Expenditures		$1.000M	$1.000M
Free Cash Flow		-$2.101M	-$8.291M
YoY Change		-13.77%	-46.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001174940
CY2023	dei	Auditor Firm AuditorFirmId	677
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent		usd
CY2023Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent		usd
CY2023	OGEN	Stock Issued During Period Value Conversion Of Series F Preferred Stock To Common Stock StockIssuedDuringPeriodValueConversionOfSeriesFPreferredStockToCommonStock		usd
CY2022	OGEN	Write Off Of In Process Research And Development WriteOffOfInProcessResearchAndDevelopment		usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables		usd
CY2022	OGEN	Stock Issued During Period Value Conversion Of Series B Preferred Stock To Common Stock StockIssuedDuringPeriodValueConversionOfSeriesBPreferredStockToCommonStock		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities		usd
CY2022	OGEN	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets		usd
CY2023	OGEN	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment		usd
CY2022	OGEN	Increase Decrease In Prepaid Research And Development IncreaseDecreaseInPrepaidResearchAndDevelopment		usd
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2022	OGEN	Issuance Of Series F Preferred Stock For Inprocess Research And Development IssuanceOfSeriesFPreferredStockForInprocessResearchAndDevelopment		usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1		usd
CY2023	OGEN	Conversion Of Stock Amount Converted ConversionOfStockAmountConverted		usd
CY2023	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1		usd
CY2023	OGEN	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued		usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross		usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment		usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent		usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent		usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent		usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent		usd
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences		usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet		usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2022	us-gaap	Short Term Lease Cost ShortTermLeaseCost		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	6701615	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4480693	shares
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2022	dei	Auditor Firm AuditorFirmId	199
CY2023	dei	Auditor Name AuditorName	Cherry Bekaert LLP
CY2023	dei	Auditor Location AuditorLocation	Tampa, Florida
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2022	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2022	dei	Auditor Location AuditorLocation	St. Petersburg, FL
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3483501	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11426785	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	382273	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2862738	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	3865774	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	14289523	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	-0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121062	usd
CY2023Q4	OGEN	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	1090750	usd
CY2022Q4	OGEN	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	-0	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9811	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	347440	usd
CY2023Q4	us-gaap	Assets Assets	4966335	usd
CY2022Q4	us-gaap	Assets Assets	14758025	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1475667	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1124197	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	312703	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	267640	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	9811	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	204447	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1798181	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1596284	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	152439	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	152439	usd
CY2023Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	1592723	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	1592723	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3080693	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3080693	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2024657	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2024657	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	3081	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2025	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	207790604	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	196977071	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-206218254	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-185562517	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3168154	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13009302	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4966335	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14758025	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	37653	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	131521	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15490604	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10072684	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5451952	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4479605	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	20942556	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	14552289	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-20904903	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-14420768	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	210394	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	135900	usd
CY2023	us-gaap	Interest Expense InterestExpense	30591	usd
CY2022	us-gaap	Interest Expense InterestExpense	15103	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	69363	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11582	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	132379	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20655737	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14288389	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-9.18
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-9.18
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2249694	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2249694	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2009234	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2009234	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13009302	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	550083	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	415169	usd
CY2022	OGEN	Conversion Of Stock Amount Converted ConversionOfStockAmountConverted	648821	usd
CY2022	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	7	usd
CY2022	OGEN	Conversion Of Stock Amount Issued ConversionOfStockAmountIssued	9	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20655737	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7290880	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-206218254	usd
CY2023	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	800000	usd
CY2023	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	466745	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	8947834	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	849927	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20655737	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	3168154	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	26486199	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	742203	usd
CY2022	OGEN	Stock Issued During Period Value Proceeds From Issuance For Common Stock StockIssuedDuringPeriodValueProceedsFromIssuanceForCommonStock	69289	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14288389	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13009302	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	13009302	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-20655737	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-14288389	usd
CY2023	OGEN	Write Off Of In Process Research And Development WriteOffOfInProcessResearchAndDevelopment	10273506	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27391	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44667	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-29956	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	10964	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	1016828	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	742203	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-6987	usd
CY2023	OGEN	Increase Decrease In Operating Lease Right Of Use Assets IncreaseDecreaseInOperatingLeaseRightOfUseAssets	-337629	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2000824	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1899612	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-347075	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	25798	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	176625	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7290880	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15228483	usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	63716	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	12000	usd
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	1000000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	127519	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-936284	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-115519	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	566046	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	564205	usd
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	849926	usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	69289	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	283880	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-494916	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7943284	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15838918	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11426785	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	27265703	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3483501	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	11426785	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	3347	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	9290	usd
CY2023	us-gaap	Notes Assumed1 NotesAssumed1	611109	usd
CY2022	us-gaap	Notes Assumed1 NotesAssumed1	528429	usd
CY2023	OGEN	Issuance Of Series F Preferred Stock For Inprocess Research And Development IssuanceOfSeriesFPreferredStockForInprocessResearchAndDevelopment	8947834	usd
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_z7t5SRYlzB83" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86D_zTzz850ej5oi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The principal areas of estimation reflected in the consolidated financial statements are stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84C_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZ4BpiqYb2c3" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86D_zZJsx8Wc9hKi">Reclassification</span></i></b> – Certain prior year amounts have been reclassified to conform to the current year presentation. The reclassification did not result in a change in the net loss. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Accounting for Mergers and Acquisition</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ASC 805, Business Combinations, provides a model for determining whether an acquisition represents a business combination. In order to be a business, the integrated set of activities of the acquired entity needs to have an input and a substantive process that together significantly contribute to the ability to create outputs. The acquired entity must also pass the “Screen Test” which involves determining whether the acquisition represents an in-substance asset acquisition based on whether the fair value of the gross assets acquired is “substantially all” concentrated in a single asset or group of similar assets. This evaluation excludes certain acquired assets such as cash, deferred taxes, and goodwill associated with deferred taxes, but includes all other gross assets, including any consideration transferred in excess of the identified assets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company accounted for the acquisition of the Odyssey neurology assets as an asset acquisition after determining that the transaction did not meet the criteria of a business combination. The Company determined that substantially all of the fair value of the gross assets acquired was concentrated in a single identifiable asset or group of similar identifiable assets, the most significant of which is the in-process research and development asset associated with the concussion product candidates. The net assets were recorded at fair value at the date of acquisition and the in-process research and development was recorded as research and development expense in the Company’s consolidated statement of operations.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84E_eus-gaap--ConcentrationRiskCreditRisk_zEj8O82DJTMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zC8N2c94ydl3">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash accounts in commercial banks, which may, at times, exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash and cash equivalents. As of December 31, 2023, the uninsured portion of this balance was $<span id="xdx_908_eus-gaap--CashUninsuredAmount_iI_c20231231_znYVj4FCAFuc">3,102,203</span>. As of December 31, 2022, the uninsured portion of this balance was $<span id="xdx_905_eus-gaap--CashUninsuredAmount_iI_c20221231_zapJLIwaxDV7">11,176,785</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	3102203	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	11176785	usd
CY2023Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable	325672	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1484301	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1363239	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	-0	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	121062	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	27391	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	44667	usd
CY2023	us-gaap	Gain Loss On Sale Of Other Assets GainLossOnSaleOfOtherAssets	52000	usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	22443	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1244947	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	246690	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	222739	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	812861	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	31101	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	7981	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	33545	usd
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1475667	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1124197	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4166666	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2023	us-gaap	Preferred Stock Voting Rights PreferredStockVotingRights	The Series E Preferred Stock had super voting rights on the proposed amendment equal to 2,500 votes per share of Series E Preferred Stock. Pursuant to the Purchase Agreement, the investors agreed to vote their common stock in favor of the amendment.
CY2023Q4	us-gaap	Notes Payable NotesPayable	312703	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	267640	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	312703	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	267640	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2471809	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	334940	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	372989	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	47333	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	17940	usd
CY2023Q4	OGEN	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	1090750	usd
CY2022Q4	OGEN	Prepaid Research And Development Expense PrepaidResearchAndDevelopmentExpense	-0	usd
CY2023Q4	OGEN	Current And Long Term Prepaid Assets CurrentAndLongTermPrepaidAssets	1473023	usd
CY2022Q4	OGEN	Current And Long Term Prepaid Assets CurrentAndLongTermPrepaidAssets	2862738	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	117000000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2000000.0	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	4160000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	260995	shares
CY2023Q4	OGEN	Class Of Warrant Or Right Outstanding Exercisable ClassOfWarrantOrRightOutstandingExercisable	260995	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.19	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.52	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.37	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.50	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0393	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0484	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0128	pure
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0309	pure
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P10Y
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	550082	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	742203	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	287858	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	139090	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	41.49
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M6D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	144204	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.11
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	38561	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	52.94
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	244733	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	20.17
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y8M23D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	74559	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	176559	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	25.02
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M18D
CY2023Q4	OGEN	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisable	48063	shares
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.59
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	19.44
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	291401	usd
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	9395	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	140000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.37
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	134000	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	3.34
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	6000	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	3.37
CY2023	OGEN	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue	451580	usd
CY2023	us-gaap	Restricted Stock Expense RestrictedStockExpense	466745	usd
CY2022	us-gaap	Restricted Stock Expense RestrictedStockExpense	0	usd
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	20045	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	26907	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5791558	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-3714988	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-5791558	usd
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-3714988	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	39810409	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37713107	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	8751	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1160775	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1119642	usd
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3417706	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2325391	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	2569559	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	46958449	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	41166891	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46958449	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41166891	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-4337705	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3000564	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1204720	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-785862	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	150533	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5342529	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3714988	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	272	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	612	usd
CY2023	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	49091	usd
CY2022	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	70826	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	46958449	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	41166891	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	5791558	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	3714988	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	153575836	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	137731183	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	46229	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	940106	usd
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4027180	usd
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	940106	usd
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	115396	usd
CY2022	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-17043	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4834847	usd
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	46229	usd
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	680042	usd
CY2023	us-gaap	Unrecognized Tax Benefits Period Increase Decrease UnrecognizedTaxBenefitsPeriodIncreaseDecrease	-31680	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4169354	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4169354	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	4834847	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y8M19D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0624	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0578	pure
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9887	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	9887	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	76	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	9811	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	191359	usd
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	229312	usd
CY2023	us-gaap	Lease Cost LeaseCost	191359	usd
CY2022	us-gaap	Lease Cost LeaseCost	229312	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	195257	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	235775	usd

Files In Submission

Name	View Source	Status
0001493152-24-011979-index-headers.html	Edgar Link	pending
0001493152-24-011979-index.html	Edgar Link	pending
0001493152-24-011979.txt	Edgar Link	pending
0001493152-24-011979-xbrl.zip	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex4-8.htm	Edgar Link	pending
ex97-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
form10-k_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ogen-20231231.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
ogen-20231231_cal.xml	Edgar Link	unprocessable
ogen-20231231_def.xml	Edgar Link	unprocessable
ogen-20231231_lab.xml	Edgar Link	unprocessable
ogen-20231231_pre.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OGEN
ORAGENICS INC Stock $ogen

2024 Q1 Form 10-K Financial Statement

#000149315224011979 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN ORAGENICS INC Stock $ogen

2024 Q1 Form 10-K Financial Statement

#000149315224011979 Filed on March 29, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OGEN
ORAGENICS INC Stock $ogen